Tadamitsu Kishimoto

USPTO Granted Patents = 41 (Patent Applications = 4)

CIPO Patents = 1

EPO Patents = 7 (Patent Applications = 3)

Average Co-Inventor Count = 2.3

ph-index = 16

Forward Citations = 1,295(Granted Patents)

Location History:

Nakano Tondabayashi-shi, Oosaka-fu, JP (1993)
Tondabayashi-shi, Osaka-fu, JP (1985 - 1994)
Tondabayashi, Osaka, JP (1997)
Tondabayashi-shi, Osaka, JP (1992 - 2002)
Tondabayashi-shi, Osaka JP (2003 - 2008)
Tondabayashi, JP (1987 - 2014)
Osaka, JP (1995 - 2022)

Company Filing History:

11 out of 947

Chugai Seiyaku Kabushiki Kaisha

Ono Pharmaceutical Co., Ltd.

patents

5. 2 out of 998

Shionogi & Company Limited

Otsuka Pharmaceutical Company, Limited

patents

8. 1 out of 15,458

University of California

patents

9. 1 out of 22

Ono Pharmaceuticals Co., Ltd.

patents

10. 22 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1985-2022

Loading Chart...

41 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11279931 - Therapeutic agent for a lung disease and/or method for screening for the same (2022-03-22),

2. 10550387 - Therapeutic agent for a lung disease and/or method for screening for the same (2020-02-04),

3. 8802092 - Mesothelioma therapeutic agent (2014-08-12),

4. 8617550 - Treatment of vasculitis with IL-6 antagonist (2013-12-31),

5. 8597644 - Method for treating psoriasis by administering an antibody to interleukin-6 receptor (2013-12-03),

6. 8562990 - Method of treating psoriatic arthritis with an IL-6 receptor antibody (2013-10-22),

7. 8119126 - Inhibiting vascularization using antibodies to CXCR4 and SDF-1 (2012-02-21),

8. 8017121 - Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component (2011-09-13),

9. 7824674 - Preventive or therapeutic agent for inflammatory bowel disease comprising IL-6 antagonist as an active ingredient (2010-11-02),

10. 7361737 - Mouse CXC chemokine receptor (2008-04-22),

11. 7320792 - Preventives or remedies for psoriasis containing as the active ingredient IL-6 antagonist (2008-01-22),

12. 7247424 - Screening method for a substance having hypoglycemic activity by using STAT-induced inhibitor of STAT function-1 (2007-07-24),

13. 7074616 - Mouse CXC chemokine receptor (2006-07-11),

14. 6770644 - Hydroxamic acid derivatives, process for the production thereof and drug containing the same as the active ingredient (2004-08-03),

15. 6723319 - Method of treating inflammatory intestinal diseases containing as the ingredient IL-6 receptors antibodies (2004-04-20),

As an AI assistant specialized in innovations, inventions, inventors, and patents, I can help you with that!

Title: The Pioneering Work of Tadamitsu Kishimoto in Lung Disease Therapies

Introduction:

Tadamitsu Kishimoto, a renowned inventor hailing from Tondabayashi, Japan, has made significant contributions to the field of healthcare with a staggering 41 patents to his name.

Latest Patents:

Among his latest patents is a groundbreaking discovery in the form of a therapeutic agent for lung diseases, along with a method for screening this agent. This innovation includes an Arid5A inhibitor crucial for combating lung diseases effectively.

Career Highlights:

Throughout his illustrious career, Kishimoto has worked with reputable companies such as Chugai Seiyaku Kabushiki Kaisha. His dedication to advancing medical treatments has led to numerous breakthroughs in the field of respiratory health.

Collaborations:

Kishimoto's impactful work has been further enriched by collaborations with esteemed professionals in the industry. Notable coworkers include Toshio Hirano and Hiroaki Ito, who have played pivotal roles in bringing his inventions to fruition.

Conclusion:

In conclusion, Tadamitsu Kishimoto's relentless pursuit of innovation in the realm of lung disease therapies has undoubtedly left an indelible mark on the field of medicine. His patents and collaborations stand as a testament to his unwavering commitment to improving healthcare outcomes globally.

This text is generated by artificial intelligence and may not be accurate.